[ad_1]
New Delhi: In revised treatment guidelines, the World Health Organization (WHO) strongly recommends against the use of two antibody drugs – sotrovimab and casirivimab-imdevimab – in Covid-19 patients, adding that these drugs may not be effective against currently prevalent variants such as Omron .
The review, carried out by WHO’s international expert guideline development group and published in the peer-reviewed journal BMJ on Friday, replaces previous conditional recommendations for the use of the two drugs.
Also read: WHO highlights omissions in report critical of UN health agency’s coronavirus response
These drugs pass Binds to the Sars-CoV-2 spike protein and neutralizes the ability of the virus to infect cells. Both received emergency use authorization from the U.S. Food and Drug Administration for the treatment of severe Covid-19 after early trials showed some effect on the Delta variant of the virus that has ravaged the world for much of 2021. “After weighing all the evidence, the panel judged that almost all well-informed patients would not choose to receive either sotrovimab or casirivimab-imdevimab,” read the note.
The group considered in vitro (lab-based) neutralization data in strongly recommending against the use of monoclonal antibodies in Covid-19 patients.
“…sotrovimab and casirivimab-imdevimab evaluated in clinical trials significantly reduced the neutralizing activity of currently circulating Sars-CoV-2 variants and their subvariants. The panel agreed that the lack of in vitro neutralizing activity strongly suggests that These monoclonal antibodies lack clinical effectiveness,” they said.
Experts in India say it is good that the WHO officially updated the guidelines because there is enough evidence that monoclonal antibodies no longer work. “In major cities in India, antibodies have been given to specific patients, but this was the case in the last wave. These drugs are directed against the spike protein, and any change in the spike protein means that unless the drugs are also modified, they will It doesn’t work. The Ministry of Health has shown this, and now even the WHO has announced it, which makes perfect sense,” said Dr Yatin Mehta, Chair of the Institute of Intensive Care and Anesthesiology at Gurugram Medanta-The Medicity.
[ad_2]
Source link
